BioNTech SE (BNTX)
- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $87.99
- As of
Kresmion compiles this page from BNTX's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
BioNTech SE (BNTX): 4 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 6-K filed 2026-10-26.
See the full BNTX dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for BNTX on one page. Preview it with sample data, then open it live with a free account.
Preview the BNTX dossierActive events for BNTX
- high13F: funds reduced
3 tracked funds reduced BNTX this 2026Q2, institutional consensus
- high13F: funds added
4 tracked funds increased BNTX this 2026Q2, institutional consensus
- mediumEarnings below estimates
Q2-2026: Missed consensus by 51.9%, EPS $-3.24 vs $-2.1328 estimate
- high13F: funds added
3 tracked funds increased BNTX this 2026Q2, institutional consensus
- high13F: large increase
CITADEL ADVISORS LLC added +156% to BNTX (2026Q2)
FREE, NO ACCOUNT
Every event on BNTX, as it fires
You are seeing 5 of 22 events recorded on BNTX since 2026-05-26.
The five above landed across 3 days. The other 17 were recorded on 2 other days. 14 of the 22 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in BNTX (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| D. E. Shaw & Co., Inc.CUSIP 09075V102 · 2026Q2 | $38.8M | 0.02% | , |
| CITADEL ADVISORS LLCCUSIP 09075V102 · 2026Q2 | $33.9M | 0.00% | , |
| Point72 Asset Management, L.P.CUSIP 09075V102 · 2026Q2 | $30.4M | 0.03% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 09075V102 · 2026Q2 | $27.2M | 0.02% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, BNTX
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
BNTX against its peers
BNTX's operating margin of -49.0% ranks in the 25th percentile of 17 Biotechnology sub-industry peers, fiscal periods ending between 2025-12-31 and 2026-03-31.
| Metric | BNTX | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 2.9B EUR | n/a | n/a | 1 |
| Revenue YoY | 4.3% | n/a | n/a | 1 |
| Gross margin | 77.6% | 87.2% | 17 | 14 |
| Operating margin | -49.0% | 12.7% | 25 | 17 |
| Net margin | -39.6% | 9.6% | 24 | 18 |
| Return on equity | -5.9% | 6.2% | 45 | 20 |
| P / E | n/a | 31.1x | n/a | 9 |
Peers (23): INSM, INCY, UTHR, ROIV, RPRX, EXEL, ASND, ALNY, NBIX, HALO, GMAB, BBIO, BIIB, SMMT, RVMD, ONC, BMRN, APGE.D, KYMR, CAI, MDGL, NUVL.D, PCVX. Left out: IVBXF (no annual filing), SBMFF (no annual filing). Fiscal periods ending between 2025-12-31 and 2026-03-31. Every figure is one full fiscal year read from one annual filing (BNTX: 20-F), reported in EUR. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow BNTX on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to BNTX for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.